Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) reported second quarter 2026 collaboration revenue of $65.0 million, up from $11.5 million a year earlier, driven by a $45 million option exercise fee from Gilead for KT-200 and a $20 million milestone from Sanofi for KT-485. Research and development expenses rose to $119.5 million, and general and administrative expenses to $21.1 million, resulting in a net loss of $61.2 million, versus $76.6 million in Q2 2025.
Kymera ended June 30, 2026 with $1.5 billion in cash, cash equivalents and investments and expects runway into 2029. Operationally, enrollment in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial completed nearly six months early, pulling expected topline data forward to year-end 2026 and supporting planned Phase 3 initiation by mid-2027. The company also advanced KT-621 in asthma, KT-579 in Phase 1 with data expected in 4Q26, and partnered programs KT-485 and KT-200 with Sanofi and Gilead.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on oral small molecule degrader medicines for immunological diseases, plans to report its second quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Investors can access the live video call and livestreamed webcast by registering through a provided link or by visiting the “News and Events” page in the Investors section of Kymera Therapeutics’ website. A replay of the webcast will be archived and made available after the event.
Kymera Therapeutics (NASDAQ: KYMR) appointed Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD, who will retire from his role after eight years and remain an advisor through year-end 2026. Dr. Rooney will lead Kymera’s global clinical development strategy and advancement of its oral immunology degrader portfolio across multiple immuno-inflammatory diseases.
According to Kymera, Dr. Rooney previously held senior immunology leadership roles at Johnson & Johnson, Eli Lilly and Roche, and has contributed to successful marketing applications for medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA® and TREMFYA®. He brings experience across small molecules, biologics, cell therapies and multiple therapeutic areas, including dermatology, respiratory, rheumatology, gastroenterology and rare diseases.
Kymera Therapeutics (NASDAQ: KYMR) appointed Elizabeth Laws, Ph.D. as Senior Vice President, Global Program Team Leader for KT-621, its first-in-class, oral STAT6 degrader for immunological diseases. She will guide global strategy and development.
KT-621 has parallel Phase 2b trials in atopic dermatitis and asthma, with data expected by year-end 2026 and late 2027, and Phase 3 atopic dermatitis trials planned by mid-2027.
Kymera Therapeutics (NASDAQ:KYMR) completed enrollment in the global Phase 2b BROADEN2 trial of KT-621 in moderate to severe atopic dermatitis nearly six months ahead of plan. Topline data are now expected by year-end 2026, with Phase 3 AD trials targeted to start by mid-2027, subject to regulators.
BROADEN2 is a randomized, double-blind, placebo-controlled, dose-ranging study of three KT-621 doses in about 200 patients over 16 weeks, with percent EASI score change at Week 16 as the primary endpoint. KT-621 also has Fast Track designation and is in a Phase 2b asthma trial with data expected in late 2027.
Kymera Therapeutics (NASDAQ: KYMR) appointed Felix J. Baker, PhD, as Chairman of the Board, effective June 24, 2026. He succeeds co-founder Bruce Booth, DPhil, who remains an Independent Director. Baker has been Kymera’s Lead Independent Director since 2024 and leads Baker Brothers Investments.
Kymera Therapeutics (NASDAQ: KYMR) reported Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults presented at the Japanese Dermatological Association meeting.
The randomized, double-blind, placebo-controlled study (24 participants) showed favorable PK, ≥98% median STAT6 degradation at Day 7, and a well-tolerated safety profile comparable to prior KT-621 studies. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027.
Kymera Therapeutics (NASDAQ: KYMR) reported first dosing in a first-in-human Phase 1 trial of KT-485 (SAR447971), an oral IRAK4 degrader, in healthy adults and hidradenitis suppurativa patients. The Sanofi-led study triggers a $20 million milestone and is part of up to $975 million in potential milestones.
The three-part trial will assess safety, tolerability, pharmacokinetics and exploratory endpoints using SAD, MAD and open-label MAD cohorts.
Kymera Therapeutics (NASDAQ: KYMR) appointed Penny Carlson as Senior Vice President, Development Operations, to oversee global clinical development operations across its oral immunology portfolio. Jeremy Chadwick will retire as Chief Operating Officer, remaining an advisor through year-end.
Carlson brings 20+ years of leadership in clinical program management, study execution and data management.
Kymera Therapeutics (NASDAQ: KYMR) reported new preclinical lupus data for KT-579, an oral IRF5 degrader. KT-579 showed disease-modifying activity in multiple lupus models, with effects described as comparable or superior to approved and clinically active agents, and consistent modulation of Type I IFN, cytokine, and B cell-driven pathways.
The ongoing Phase 1 healthy volunteer trial is assessing safety, tolerability, PK/PD, and IRF5 degradation, with data expected in 2H26 and a patient proof-of-concept trial planned, likely in lupus.